iSpecimen Inc. (ISPC) Analyse boursière

Présentation de l'entreprise

iSpecimen Inc. operates a specialized marketplace designed to supply biospecimens to life science researchers located worldwide. The company develops and operates the iSpecimen Marketplace, a proprietary online platform that facilitates connections between medical researchers requiring access to subjects, samples, and data with hospitals and laboratories. This entity functions within the Healthcare sector, specifically inside the Diagnostics & Research industry, where it facilitates critical data exchange for scientific advancement. The company currently holds a market capitalization of $4.30M and reported trailing twelve-month revenue of $1.93M, while the employee count is not disclosed in available public filings. These valuation and revenue figures indicate that iSpecimen Inc. operates as a micro-cap entity with a relatively small market footprint, suggesting limited scale in the broader healthcare diagnostics ecosystem.

Santé financière

The company reported total revenue of $1.93M for the trailing twelve months, yet this generated a net loss of $10,487,532, revealing a severe disconnect between top-line sales and bottom-line profitability due to high operational costs. EBITDA for the period stood at $-8,717,890, indicating that core operating activities are not generating sufficient cash to cover interest and principal payments on debt. Free cash flow is negative at $-2,782,585, which signifies that the company is burning cash and lacks the internal financial flexibility to fund operations or growth without external capital injections. The gross margin is extremely low at 1.2%, suggesting that the cost of goods sold consumes nearly the entirety of revenue before operating expenses are considered. The operating margin is severely negative at -5192.9%, and the profit margin is listed at 0.0%, highlighting that operating expenses and other costs drastically outweigh gross profits. Liquidity analysis shows the company holds $6.88M in cash against $268,798 in debt, yet the debt-to-equity ratio is elevated at 8.70, indicating a highly leveraged balance sheet relative to shareholders' equity. The current ratio stands at 1.12, which suggests the company possesses just enough current assets to cover its current liabilities, leaving little margin for error in short-term liquidity management. Return on Equity is -327.8% and Return on Assets is -59.4%, metrics that reveal management has not yet been effective at generating returns on the capital invested by shareholders or the asset base.

Évaluation de la valorisation

Trailing P/E ratio is not applicable due to negative earnings, while the forward P/E is listed as -0.18, implying that the market anticipates a return to profitability or is pricing the stock based on non-traditional earnings expectations. The price-to-book ratio is 0.46, indicating that the market values the company at less than half of its net asset value, which often suggests a deep discount or significant concerns regarding asset quality. The price-to-sales ratio is 2.23, and the EV/EBITDA is 0.27; these alternative metrics suggest the company is valued very cheaply relative to its sales and enterprise value, though such low multiples for a growth-oriented firm often reflect high risk. The stock has traded between a 52-week high of $3.18 and a 52-week low of $0.14, illustrating extreme volatility over the past year. The beta value is 1.98, which indicates that the stock price is significantly more volatile than the broader market, moving nearly twice as much in either direction relative to market index changes.

Growth & Income

Revenue growth year-over-year has contracted sharply by -96.5%, while earnings growth is not applicable due to the company's negative earnings position. The substantial decline in revenue indicates that the company's sales base is shrinking or failing to capture market demand, and since earnings are already negative, there is no earnings growth to compare against revenue trends. As a non-dividend payer, iSpecimen Inc. does not distribute a dividend yield or payout ratio, meaning the company retains all available cash flow rather than returning it to shareholders. The overall growth and income profile is characterized by significant revenue contraction and a complete lack of dividend income, positioning the asset as a high-risk investment reliant entirely on future operational turnaround rather than current profitability or income generation.